If a company is developing its first product, at what point does it become an ineligible company?

A biomedical startup company is considered to be ineligible if it has begun a “government regulatory approval process”.  The Standards’ section on eligibility explains that the point of entry into this process to be the actual submission of the Investigational New Drug Application (IND). This must be approved before clinical trials begin.  Once a company submits the IND, it would become an ineligible company.  For medical devices, this would be when a company submits a premarket approval (PMA).


CME Watch

AOE’s video blog that provides updates on the CME/CE industry. AOE’s Managing Director Annika Borvansky gives insights on CME/CE current events and best practices.

More >


Weekly Compliance Tip

What are the parameters on group size for a Merit-based Incentive Payment System (MIPS) Improvement Activity? 

The ACCME does not have restrictions in place for this.  MIPS activities can…

More >


Phone: (303) 557-0859
E-mail: inquire@aoeconsulting.com
AOE Consulting, LLC
8156-E S. Wadsworth Blvd.
Suite 198
Littleton, CO 80128